Lead Product(s): BGE-117
Therapeutic Area: Musculoskeletal
Highest Development Status: Phase I Product Type: Undisclosed
Partner/Sponsor/Collaborator: BioAge Labs
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 29, 2020
BioAge gets an exclusive worldwide license to develop and commercialize Taisho's clinical-stage Hypoxia-inducible factor-prolyl hydroxylase inhibitor, BGE-117, to treat multiple diseases of aging.